COMPOUND WITH CONFIDENCE: PCCA Membership, $795/month.
Stay current on PCCA news and events, market trends, and all things compounding!
Erin Michael, MBA, MS, CPhT, PCCA's Director of Outside Sales wants to let pharmacists know that a little courtesy goes a long, long way when building customer relationships.
PCCA's Clinical Services team is populated with hard-working, dedicated pharmacy professionals who strive each day to make a difference in pharmacy compounding. As a team, they act as a cornerstone of PCCA's abiding desire to provide pharmacies with answers to tough questions. The Clinical Services Spotlight is a limited series of articles designed to highlight a singular member of the Clinical Services team. This second article focuses on Nat Jones, RPh, FIACP, a man who was born to stand in the spotlight.
In the first part of this article, Pamela, Nat, and Sara shined a light on new health risk information compounders should consider when providing bioidentical hormone replacement therapy. In this second part of the article, they dive deeper into the BHRT conversation, discussing compounded topical estrogen as an option.
Compounded bioidentical hormone replacement therapy (BHRT) is an important treatment option for women around the world. Colleagues and patients alike come to PCCA experts Pamela Smith, Nat Jones and Sara Hover for guidance. In this article, our three experts cover this all-too-important topic in the HRT conversation, on what current literature says about the usage of oral vs. topical estrogen discussion.
Congratulations to Karen Francis, RPh, owner of Compounding Wellness Pharmacy located in St. John's, Newfoundland and Labrador, Canada for being our November Profile in Personalized Medicine. These profiles celebrate members of the PCCA family who have proven to be champions of Pharmacy Compounding by providing the highest quality of service to their patients.
PCCA's Director of Formulation Development Melissa Merrell Rhoads, PharmD, provides part two in a set of posts detailing the upcoming changes to our formulas based upon the new USP guidelines. This particular section focuses on USP <797>.
PCCA's Director of Formulation Development Melissa Merrell Rhoads, PharmD, provides part one in a set of posts detailing the upcoming changes to our formulas based upon the new USP guidelines.